source
- Eli Lilly inks $5.9 billion partnership with Stipple Bio to develop precision oncology drugsEli Lilly has announced a partnership with Stipple Bio that could be worth up to $5.9 billion. The collaboration will focus on oncology drug candidates designed to target tumor cells more precisely…
- Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trialSellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…